Anthropic, the company behind the Claude AI assistant, is moving into pharmaceutical research. According to India Today, the firm has entered the healthcare AI space with a drug discovery programme, a step that adds it to a widening race to apply artificial intelligence in medicine.
The centerpiece is a new tool. According to NewsBytesApp, Anthropic has launched a drug discovery program targeting neglected diseases and introduced Claude Science, an AI platform designed to streamline scientific research workflows. Neowin describes Claude Science as a dedicated app built specifically for scientists.
The emphasis on neglected diseases is notable. These are conditions that often receive limited commercial research attention, and NewsBytesApp reports they are the focus of Anthropic's new program.
This is not a one-off experiment. Citeline frames the launch as Anthropic going deeper into drug development with Claude Science, suggesting the company sees scientific research as a serious application of its technology rather than a side project.
Anthropic joins a crowded field. India Today notes the move places the company within a broadening race to bring AI into medicine, where the promise is that software can help researchers sift through data and design experiments faster than traditional methods allow.
The available sources describe the announcement and its goals but do not detail specific results, timelines, partners, or the diseases being targeted.
Why it matters: if AI tools like Claude Science can speed up the slow, expensive work of discovering new medicines, they could eventually help bring treatments to patients faster, including for diseases that the pharmaceutical industry has historically overlooked.